Cancer Patient Protection Act of 2013

HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologics under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP), generally including CMS' proposed Part B Drug payment demonstration rule. Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Caner Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 506/H.R. 696(Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", HR 1919 "Safeguarding America's Pharmaceuticals Act", Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54), Pharma supply chain issues, Issues related to 340b program; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program

Client expense: $1,310,600 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) CMS - (Sunshine, AMP and NADAC) SGR (H.R. 2810, S. 1871) Medicare Extenders (H.R. 3402) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) CMS - (Sunshine, AMP and NADAC) SGR (H.R. 2810, S. 1871) Medicare Extenders (H.R. 3402) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: $420,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts. S. 1277, S. 1657, H.R. 3392 & H.R. 4096 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services

Client expense: $420,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR 800, prompt pay legislation; health IT and meaningful use; radiation and reimbursement issues; SGR Medicare physician payments; H.R.1416 Cancer Patient Protection Act of 2013; H.R. 2869, Medicare Patient Access to Cancer Treatment Act of 2013

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Repeal Medicare Sustainable Growth Rate formula; Monitor implementation, P.L. 111-148; Extend Section 3111, P.L. 111-148; H.R. 4015 / S. 2000, SGR Repeal and Medicare Provider Payment Modernization Act; H.R. 2810, Medicare Patient Access and Quality Improvement Act of 2013; S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013; H.R. 4302, Protecting Access to Medicare Act; H.R. 1416, Cancer Patient Protection Act; H.R. 2305 / S. 1123, Preventing and Reducing Improper Medicare and Medicaid Expenditures Act; H.R. 5481, To continue the use of a 3-month quarter EHR reporting period for health care providers to demonstrate meaningful use for 2015 under EHR incentive payment programs; H.R. 800, To exclude prompt pay discounts from ASP formula

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

21st Century Cures Initiative Patient Access to Approved DrugsReimbursement for Innovative Products H.R. 1416: Cancer Patient Protection Act of 2013 Medicare Part B Physician-Administered Products Medicare Part D Prescription Drug Program CMS Proposed Rule on Protected Classes

Client expense: $2,090,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR), White House Office

Affordable Care Act Implementation Third Party Support of Patient Premiums and Cost-Sharing Obligations21st Century Cures Initiative Biomarkers and Regulatory Science Improvements Communication with Healthcare Professionals Expanded Access to Investigational Drugs Expedited Pathways FDA Hiring Flexibility FDA Management and Financial Accountability Innovation Incentives Longitudinal Study of Chronic Diseases Patient Access to Approved Drugs Patient-Focused Drug Development Use of Real-World Evidence Vaccine and Anti-Microbial Resistance Product Development and Incentives Combating Antibiotic-Resistant Bacteria (CARB) Initiative Biosimilars Biosimilar User Fee Act Implementation Colombia Biologics Regulations Implementation of Affordable Care Act Interchangeability and Pharmacy Substitution Naming Patent Certification Funding for National Institutes of Health H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015 Funding for Centers for Disease Control and Prevention Vaccine Programs H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015 340B Drug Pricing Program H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015 Implementation of Affordable Care Act Program Implementation & Oversight Funding for FDA H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015 Independent Payment Advisory Board Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015 TransPacific Partnership Regulatory Transparency Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade and Investment Partnership Regulatory Harmonization Reimbursement Issues Intellectual Property IssuesReimbursement for Innovative Products H.R. 1416: Cancer Patient Protection Act of 2013 Medicare Part B Physician-Administered Products Medicare Part D Prescription Drug Program CMS Proposed Rule on Protected Classes Sequestration of PDUFA Fees HR 2725: Food and Drug Administration Safety over Sequestration Act of 2013 H.R. 83: Consolidated and Further Continuing Appropriations Act for FY 2015 Drug Evaluation and Review Implementation of the FDA Safety and Innovation Act Orphan Drug Act Tax Credit Clinical Trial Data Sharing and Disclosure Canadian Policies European Policies Sunshine Act Implementation

Client expense: $2,090,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR), White House Office

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1416, Cancer Patient Protection Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014 21st Century Cures Initiatives

Client expense: $370,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 806, H.R. 800 & H.R. 1416 relating to Average Sales Price

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow-on biologics; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Regulatory and legislative activities regarding 340B program; Issues relating to biologics; S. 959 "Pharmaceutical Compounding Quality and Accounting Act, HR 1416 "Cancer Patient Protection Act of 2013", S.957, "Drug Supply Chain Security", HR 1919 "Safeguarding America's Pharmaceuticals Act"; Issues related to the implementation of the Affordable Care Act of 2010; issues related to biosimilars; Issues concerning clinical trials; issues concerning drug compounding. Implementation of Patient Protection and Affordable Care Act. Federal Drug. Drug pricing under 340B program; Medical reimbursement - advocacy on behalf of maintaining ASP+6%, 340B Drug Discounting Program - education of Congress on unintended growth of program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; PHA: Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies.

Client expense: $1,090,200 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

**see addendum pageAverage Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) SGR (H.R. 2810, S. 1871) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 8; H.R. 800; S. 806; H.R.1416; H.R. 4709

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R.1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R.4709, S.1277, S.1657, H.R.3392, H.R.4096 & S. 2862 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148). Monitor federal issues and legislation associated with health care policy. Monitor passage and implementation of Consolidated and Further Continuing Appropriations Act, 2015 (P.L. 113-235). H.R. 460, Patients Access to Treatment Act of 2013. H.R. 1416, Cancer Patient Protection Act of 2013. H.R. 1429, Scleroderma Research and Awareness Act of 2013. H.R. 1827, Pediatric Subspecialty and Mental Health Workforce Reauthorization Act of 2013. H.R. 2663, to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. S. 1422, A bill to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. H.R. 2810, Medicare Patient Access and Quality Improvement Act of 2013. H.R. 4282, Creating Access to Residency Education Act of 2014. H.R. 4302, Protecting Access to Medicare Act. H.R. 5481, To continue the use of a 3-month quarter HER reporting period for health care providers to demonstrate meaningful use for 2015 under the Medicare and Medicaid HER incentive payment programs, and for other purposes. S. 2658, Accelerating Biomedical Research Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148). Monitor federal issues and legislation associated with health care policy. Monitor passage and implementation of Consolidated and Further Continuing Appropriations Act, 2015 (P.L. 113-235). H.R. 460, Patients Access to Treatment Act of 2013. H.R. 1416, Cancer Patient Protection Act of 2013. H.R. 1429, Scleroderma Research and Awareness Act of 2013. H.R. 1827, Pediatric Subspecialty and Mental Health Workforce Reauthorization Act of 2013. H.R. 2663, to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. S. 1422, A bill to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings. H.R. 2810, Medicare Patient Access and Quality Improvement Act of 2013. H.R. 4282, Creating Access to Residency Education Act of 2014. H.R. 4302, Protecting Access to Medicare Act. H.R. 5481, To continue the use of a 3-month quarter HER reporting period for health care providers to demonstrate meaningful use for 2015 under the Medicare and Medicaid HER incentive payment programs, and for other purposes. S. 2658, Accelerating Biomedical Research Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; health information technology; application of the sequester to cancer drug reimbursement (HR 1416 - the Cancer Patient Protection Act of 2013); prompt pay discount (HR 800 Prompt Pay Discount Legislation); safety and security of the prescription drug supply chain. Oncology payment disparities in Medicare (HR 2869)

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.

Client expense: $770,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

S. 959, "Pharmaceutical Compounding Quality and Accounting Act" H.R. 1416, "Cancer Patient Protection Act of 2013" S. 957, "Drug Supply Chain Security" H.R. 1919, " Safeguarding America's Pharmaceuticals Act"

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.

Client expense: Not reported · Firm income: $770,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

S. 959, "Pharmaceutical Compounding Quality and Accounting Act" H.R. 1416, "Cancer Patient Protection Act of 2013" S. 957, "Drug Supply Chain Security" H.R. 1919, " Safeguarding America's Pharmaceuticals Act"

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.1416, Cancer Patient Protection Act of 2013; pharma supply chain issues; S.2007, Preventing Regulatory Overreach To Enhance Care Technology Act of 2014 (PROTECT Act); issues related to the 340B Program.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 800, H.R. 1416, S.806); PPACA Implementation (PL 111-148); Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: $257,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

The Sustainable Growth Rate, HR 4015/S 2000 SGR Repeal and Medicare Provider Payment Modernization Act; HR 1416, Cancer Patient and Protection Act of 2013

Client expense: $79,365 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE